Actively Recruiting

Phase 2
All Genders
NCT05501756

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Led by Children's Hospital Medical Center, Cincinnati · Updated on 2025-07-17

60

Participants Needed

1

Research Sites

294 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.

CONDITIONS

Official Title

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undergoing allogeneic HCT at CCHMC with an alemtuzumab-containing preparative regimen for non-malignant diseases
  • For the first 7 patients, must have a 10/10 HLA matched related or unrelated stem cell donor, or receive a CD34+ selected stem cell product
  • After the first 7 patients, any donor match may be allowed after data review by clinicians and the principal investigator
Not Eligible

You will not qualify if you...

  • History of anaphylaxis to alemtuzumab
  • Previously received alemtuzumab and have not cleared it before starting preparative regimen
  • Life expectancy less than 4 weeks
  • Receiving dialysis or plasmapheresis at the start of conditioning regimen
  • Failure to sign informed consent or inability to undergo consent process
  • Medically unable to provide specimens needed for the study
  • Unable to tolerate subcutaneous dosing due to severe skin conditions
  • Diagnosis of cancer
  • Clinical condition preventing successful pharmacokinetic modeling, such as active flaring of hemophagocytic lymphohistiocytosis
  • Presence of substances interfering with accurate alemtuzumab measurement before dosing

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

Loading map...

Research Team

C

Caitlin Cottrell

CONTACT

R

Richard Cooper

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation | DecenTrialz